litlas
Log inCreate account

Peter C. Isakson

Active 1975–2005

61
Papers
20,231
Citations
61
h-index
61
i10-index

Citations

Citations per year for Peter C. Isakson1943: 1 citations1962: 2 citations1975: 1 citations1976: 3 citations1977: 16 citations1978: 24 citations1979: 16 citations1980: 11 citations1981: 18 citations1982: 25 citations1983: 24 citations1984: 18 citations1985: 16 citations1986: 14 citations1987: 17 citations1988: 17 citations1989: 8 citations1990: 25 citations1991: 32 citations1992: 26 citations1993: 38 citations1994: 39 citations1995: 68 citations1996: 100 citations1997: 172 citations1998: 206 citations1999: 343 citations2000: 454 citations2001: 395 citations2002: 395 citations2003: 360 citations2004: 274 citations2005: 233 citations2006: 227 citations2007: 195 citations2008: 123 citations2009: 122 citations2010: 146 citations2011: 90 citations2012: 88 citations2013: 77 citations2014: 94 citations2015: 65 citations2016: 51 citations2017: 60 citations2018: 35 citations2019: 205 citations2020: 195 citations2021: 143 citations2022: 114 citations2023: 76 citations2024: 121 citations2025: 52 citations2026: 2 citations1944–1961: no citations, so these years are not shown1963–1974: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,772 citing papers, 35% of this breakdownUnited Kingdom: 301 citing papers, 5.9% of this breakdownChina: 248 citing papers, 4.9% of this breakdownGermany: 241 citing papers, 4.8% of this breakdownJapan: 241 citing papers, 4.7% of this breakdownItaly: 201 citing papers, 4% of this breakdownCanada: 189 citing papers, 3.7% of this breakdownIndia: 169 citing papers, 3.3% of this breakdownEgypt: 145 citing papers, 2.9% of this breakdownFrance: 113 citing papers, 2.2% of this breakdownSpain: 110 citing papers, 2.2% of this breakdownSaudi Arabia: 95 citing papers, 1.9% of this breakdown
0%35%Other 24.5%

Institutions

Fields

  • Medicine62.2%
  • Biochemistry, Genetics and Molecular Biology11.8%
  • Neuroscience5.8%
  • Immunology and Microbiology5.7%
  • Chemistry4.4%
  • Pharmacology, Toxicology and Pharmaceutics3.1%
  • Other7%

Topics

  • Inflammatory mediators and NSAID effects15.1%
  • Estrogen and related hormone effects4%
  • Eicosanoids and Hypertension Pharmacology3.8%
  • Synthesis and biological activity2.8%
  • Computational Drug Discovery Methods2.1%
  • Neuroinflammation and Neurodegeneration Mechanisms1.4%
  • Other70.8%

Coauthors

All papers

Open in search
  1. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

    Authors: Ravi G. Kurumbail, Anna M. Stevens, James K. Gierse, Joseph J. McDonald, Roderick A. Stegeman, Jina Y. Pak, Daniel Gildehaus, Julie M. iyashiro, Thomas D. Penning, Karen Seibert, Peter C. Isakson, William C. Stallings - Nature 1996 cited by 1,914

  2. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)

    Authors: Thomas D. Penning, John J. Talley, Stephen R. Bertenshaw, Jeffery S. Carter, Paul W. Collins, Stephen Docter, Matthew J. Graneto, Len F. Lee, James W. Malecha, Julie M. Miyashiro, Roland S. Rogers, D. Joseph Rogier, Stella S. Yu, Gary D. Anderson, Earl G. Burton, J. Nita Cogburn, Susan A. Gregory, Carol M. Koboldt, William E. Perkins, Karen Seibert, Amy W. Veenhuizen, Yan Y. Zhang, Peter C. Isakson - Journal of Medicinal Chemistry 1997 cited by 1,960

  3. Pharmacological analysis of cyclooxygenase-1 in inflammation

    Authors: Chris Smith, Yan Zhang, Carol M. Koboldt, Jerry Muhammad, Ben S. Zweifel, Alex Shaffer, John J. Talley, Jaime L. Masferrer, Karen Seibert, Peter C. Isakson - National Academy of Sciences, Proceedings of the National Academy of Sciences 1998 cited by 811

  4. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis.

    Authors: Graham Anderson, Scott D. Hauser, Kelly L. McGarity, Magdalena Bremer, Peter C. Isakson, S A Gregory - Journal of Clinical Investigation 1996 cited by 572

  5. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.

    Authors: Karen Seibert, Y Zhang, K. Leahy, Scott D. Hauser, Jaime L. Masferrer, W Perkins, L Lee, Peter C. Isakson - National Academy of Sciences, Proceedings of the National Academy of Sciences 1994 cited by 1,562

  6. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

    Authors: Jaime L. Masferrer, Ben S. Zweifel, Pamela T. Manning, Scott D. Hauser, K. Leahy, Walter G. Smith, Peter C. Isakson, Karen Seibert - National Academy of Sciences, Proceedings of the National Academy of Sciences 1994 cited by 1,315

  7. Anti-inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis

    Authors: Lee S. Simon, Arthur L. Weaver, David Y. Graham, Alan Kivitz, Peter E. Lipsky, Richard C. Hubbard, Peter C. Isakson, Kenneth M. Verburg, Shawn Yu, William W. Zhao, Gilbert Geis - JAMA 1999 cited by 804

  8. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison

    Authors: Paul Emery, H. Zeidler, Tore K Kvien, Mario Guslandi, R. Naudin, Helen Stead, Kenneth M. Verburg, Peter C. Isakson, Richard C. Hubbard, Gilbert Geis - The Lancet 1999 cited by 540

  9. Effects of Celecoxib, a Novel Cyclooxygenase‐2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial

    Authors: Philip T. Leese, Richard C. Hubbard, Aziz Karim, Peter C. Isakson, Shawn Yu, Gilbert Geis - The Journal of Clinical Pharmacology 2000 cited by 374

  10. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo.

    Authors: Joseph P. Portanova, Y Zhang, Graham Anderson, Scott D. Hauser, Jaime L. Masferrer, Karen Seibert, S A Gregory, Peter C. Isakson - The Journal of Experimental Medicine 1996 cited by 420

  11. 1,2-Diarylcyclopentenes as Selective Cyclooxygenase-2 Inhibitors and Orally Active Anti-inflammatory Agents

    Authors: James J. Li, Gary D. Anderson, Earl G. Burton, J. Nita Cogburn, Joe Collins, Danny J. Garland, Susan A. Gregory, H. T. Huang, Peter C. Isakson - Journal of Medicinal Chemistry 1995 cited by 177

  12. Leukocytes synthesize angiotensinogen.

    Authors: R. Ariel Gómez, Laura L. Norling, N. Wilfong, Peter C. Isakson, Kevin R. Lynch, Randy A. Hock, P. J. Quesenberry - Hypertension 1993 cited by 93

  13. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.

    Authors: Hongmiao Sheng, Jian‐Hua Shao, Susan C. Kirkland, Peter C. Isakson, Robert J. Coffey, Jason D. Morrow, R. Daniel Beauchamp, Raymond N. DuBois - Journal of Clinical Investigation 1997 cited by 722

  14. T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells.

    Authors: Peter C. Isakson, Ellen Puré, E S Vitetta, Peter H. Krammer - The Journal of Experimental Medicine 1982 cited by 447

  15. Treatment of Osteoarthritis With Celecoxib, a Cyclooxygenase-2 Inhibitor: A Randomized Controlled Trial

    Authors: W. Bensen, Justus J. Fiechtner, James I. McMillen, William W. Zhao, Shawn Yu, Emmett M. Woods, Richard C. Hubbard, Peter C. Isakson, Kenneth M. Verburg, Gilbert Geis - Mayo Clinic Proceedings 1999 cited by 351

  16. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia

    Authors: Masaki Nakayama, Koichi Uchimura, Raymond L. Zhu, Tetsuya Nagayama, Marie E. Rose, R. Anne Stetler, Peter C. Isakson, Jun Chen, Steven H. Graham - National Academy of Sciences, Proceedings of the National Academy of Sciences 1998 cited by 345

  17. INTERLEUKIN-6 STIMULATES ANTERIOR PITUITARY HORMONE RELEASEIN VITRO.

    Authors: Bryan L. Spangelo, Allan M. Judd, Peter C. Isakson, Robert M. MacLeod - Endocrinology 1989 cited by 323

  18. Cyclooxygenases and the Central Nervous System

    Authors: Walter E. Kaufmann, Katrin I. Andreasson, Peter C. Isakson, Paul F. Worley - Prostaglandins 1997 cited by 283

  19. Kinetic basis for selective inhibition of cyclo-oxygenases

    Authors: James K. Gierse, Carol M. Koboldt, Mark C. Walker, Karen Seibert, Peter C. Isakson - Biochemical Journal 1999 cited by 279

  20. 1,2-Diarylpyrroles as Potent and Selective Inhibitors of Cyclooxygenase-2

    Authors: Ish Khanna, Richard M. Weier, Yi Yu, Paul W. Collins, Julie M. Miyashiro, Carol M. Koboldt, Amy W. Veenhuizen, J L Currie, Karen Seibert, Peter C. Isakson - Journal of Medicinal Chemistry 1997 cited by 169

  21. 1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents

    Authors: Ish Khanna, Richard M. Weier, Yi Yu, Xiang D. Xu, Francis J. Koszyk, Paul W. Collins, Carol M. Koboldt, Amy W. Veenhuizen, William E. Perkins, J J Casler, Jaime L. Masferrer, Yan Y. Zhang, Susan A. Gregory, Karen Seibert, Peter C. Isakson - Journal of Medicinal Chemistry 1997 cited by 153

  22. Molecular cloning and expression of human leukotriene-C4 synthase.

    Authors: D. Welsch, David Creely, Scott D. Hauser, Karl J. Mathis, Gwen G. Krivi, Peter C. Isakson - National Academy of Sciences, Proceedings of the National Academy of Sciences 1994 cited by 143

  23. Cyclooxygenase-2 In Human Pathological Disease

    Authors: Alane Koki, Nasir Khan, B. Mark Woerner, Andrew J. Dannenberg, Lisa Olson, Karen Seibert, Dorothy Edwards, M.M. Hardy, Peter C. Isakson, Jaime L. Masferrer - Advances in experimental medicine and biology 2002 cited by 133

  24. Valdecoxib: Assessment of Cyclooxygenase-2 Potency and Selectivity

    Authors: James K. Gierse, Yan Zhang, William F. Hood, Mark C. Walker, Jennifer S. Trigg, Timothy J. Maziasz, Carol M. Koboldt, Jerry Muhammad, Ben S. Zweifel, Jaime L. Masferrer, Peter C. Isakson, Karen Seibert - Journal of Pharmacology and Experimental Therapeutics 2005 cited by 79